tiprankstipranks
Baxter International Inc (BAX)
NYSE:BAX
US Market
BAX
Baxter International
RESEARCH TOOLSreports
Want to see BAX full AI Analyst Report?

Baxter International (BAX) Stock Forecast & Price Target

1,618 Followers
See the Price Targets and Ratings of:

BAX Analyst Ratings

Hold
11Ratings
Hold
1 Buy
10 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Baxter
International
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BAX Stock 12 Month Forecast

Average Price Target

$25.90
▲(15.63% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Baxter International in the last 3 months. The average price target is $25.90 with a high forecast of $29.00 and a low forecast of $21.00. The average price target represents a 15.63% change from the last price of $22.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","30":"$30","18.75":"$18.75","22.5":"$22.5","26.25":"$26.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,18.75,22.5,26.25,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.16,26.37846153846154,26.596923076923076,26.815384615384616,27.033846153846152,27.252307692307692,27.470769230769232,27.689230769230768,27.907692307692308,28.126153846153848,28.344615384615384,28.563076923076924,28.78153846153846,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.16,26.14,26.12,26.1,26.08,26.06,26.04,26.02,26,25.98,25.959999999999997,25.939999999999998,25.919999999999998,{"y":25.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.16,25.763076923076923,25.366153846153846,24.96923076923077,24.572307692307692,24.175384615384615,23.77846153846154,23.38153846153846,22.984615384615385,22.587692307692308,22.19076923076923,21.793846153846154,21.396923076923077,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.773,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.652,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.324,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.441,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.06,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.09,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.849,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.679,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.771,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.201,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.69,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.16,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$29.00Average Price Target$25.90Lowest Price Target$21.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on BAX
Robbie Marcus
J.P. Morgan
J.P. Morgan
$26
Hold
16.07%
Upside
Reiterated
08/06/26
J.P. Morgan Sticks to Their Hold Rating for Baxter International (BAX)
Wells Fargo Analyst forecast on BAX
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$19→$23
Hold
2.68%
Upside
Assigned
07/31/26
Baxter International (BAX) Gets a Hold from Wells Fargo
Deutsche Bank Analyst forecast on BAX
Pito Chickering
Deutsche Bank
Deutsche Bank
$20→$27
Hold
20.54%
Upside
Reiterated
07/31/26
Baxter price target raised to $27 from $20 at Deutsche BankBaxter price target raised to $27 from $20 at Deutsche Bank
TD Cowen Analyst forecast on BAX
Josh Jennings
TD Cowen
TD Cowen
$24→$29
Hold
29.46%
Upside
Reiterated
07/31/26
Analysts Conflicted on These Healthcare Names: Karyopharm Therapeutics (NASDAQ: KPTI), Baxter International (NYSE: BAX) and Alnylam Pharma (NASDAQ: ALNY)
Citi Analyst forecast on BAX
Joanne Wuensch
Citi
Citi
$17→$28
Hold
25.00%
Upside
Upgraded
07/31/26
Baxter upgraded to Neutral from Sell at CitiBaxter upgraded to Neutral from Sell at Citi
Stifel Nicolaus Analyst forecast on BAX
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$24→$28
Hold
25.00%
Upside
Reiterated
07/31/26
Baxter price target raised to $24 from $19 at StifelBaxter price target raised to $24 from $19 at Stifel
Bank of America Securities Analyst forecast on BAX
Travis Steed
Bank of America Securities
Bank of America Securities
$24→$28
Hold
25.00%
Upside
Reiterated
07/30/26
Travis Steed Maintains Hold on Baxter, Lifts Price Target to $28 Amid Improved Growth but Gradual Earnings Outlook
UBS Analyst forecast on BAX
Patrick Wood
UBS
UBS
$19→$25
Hold
11.61%
Upside
Assigned
07/28/26
Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Incyte (NASDAQ: INCY) and Argenx Se (NASDAQ: ARGX)
Goldman Sachs Analyst forecast on BAX
David Roman
Goldman Sachs
Goldman Sachs
$19→$21
Hold
-6.25%
Downside
Assigned
07/15/26
Baxter price target raised to $21 from $19 at Goldman SachsBaxter price target raised to $21 from $19 at Goldman Sachs
Evercore ISI Analyst forecast on BAX
Vijay Kumar
Evercore ISI
Evercore ISI
$22→$24
Buy
7.14%
Upside
Reiterated
07/06/26
Baxter price target raised to $24 from $22 at Evercore ISIBaxter price target raised to $24 from $22 at Evercore ISI
Argus Research Analyst forecast on BAX
Steven Silver
Argus Research
Argus Research
―
Hold
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Baxter International (NYSE: BAX) and Capricor Therapeutics (NASDAQ: CAPR)
Barclays Analyst forecast on BAX
Matt Miksic
Barclays
Barclays
$25→$27
Buy
20.54%
Upside
Reiterated
05/04/26
Analysts Are Bullish on Top Healthcare Stocks: Alkermes (ALKS), Baxter International (BAX)
Jefferies Analyst forecast on BAX
Matthew Taylor
Jefferies
Jefferies
$21→$19
Hold
-15.18%
Downside
Reiterated
02/12/26
Baxter price target lowered to $19 from $21 at JefferiesBaxter price target lowered to $19 from $21 at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on BAX
Robbie Marcus
J.P. Morgan
J.P. Morgan
$26
Hold
16.07%
Upside
Reiterated
08/06/26
J.P. Morgan Sticks to Their Hold Rating for Baxter International (BAX)
Wells Fargo Analyst forecast on BAX
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$19→$23
Hold
2.68%
Upside
Assigned
07/31/26
Baxter International (BAX) Gets a Hold from Wells Fargo
Deutsche Bank Analyst forecast on BAX
Pito Chickering
Deutsche Bank
Deutsche Bank
$20→$27
Hold
20.54%
Upside
Reiterated
07/31/26
Baxter price target raised to $27 from $20 at Deutsche BankBaxter price target raised to $27 from $20 at Deutsche Bank
TD Cowen Analyst forecast on BAX
Josh Jennings
TD Cowen
TD Cowen
$24→$29
Hold
29.46%
Upside
Reiterated
07/31/26
Analysts Conflicted on These Healthcare Names: Karyopharm Therapeutics (NASDAQ: KPTI), Baxter International (NYSE: BAX) and Alnylam Pharma (NASDAQ: ALNY)
Citi Analyst forecast on BAX
Joanne Wuensch
Citi
Citi
$17→$28
Hold
25.00%
Upside
Upgraded
07/31/26
Baxter upgraded to Neutral from Sell at CitiBaxter upgraded to Neutral from Sell at Citi
Stifel Nicolaus Analyst forecast on BAX
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$24→$28
Hold
25.00%
Upside
Reiterated
07/31/26
Baxter price target raised to $24 from $19 at StifelBaxter price target raised to $24 from $19 at Stifel
Bank of America Securities Analyst forecast on BAX
Travis Steed
Bank of America Securities
Bank of America Securities
$24→$28
Hold
25.00%
Upside
Reiterated
07/30/26
Travis Steed Maintains Hold on Baxter, Lifts Price Target to $28 Amid Improved Growth but Gradual Earnings Outlook
UBS Analyst forecast on BAX
Patrick Wood
UBS
UBS
$19→$25
Hold
11.61%
Upside
Assigned
07/28/26
Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Incyte (NASDAQ: INCY) and Argenx Se (NASDAQ: ARGX)
Goldman Sachs Analyst forecast on BAX
David Roman
Goldman Sachs
Goldman Sachs
$19→$21
Hold
-6.25%
Downside
Assigned
07/15/26
Baxter price target raised to $21 from $19 at Goldman SachsBaxter price target raised to $21 from $19 at Goldman Sachs
Evercore ISI Analyst forecast on BAX
Vijay Kumar
Evercore ISI
Evercore ISI
$22→$24
Buy
7.14%
Upside
Reiterated
07/06/26
Baxter price target raised to $24 from $22 at Evercore ISIBaxter price target raised to $24 from $22 at Evercore ISI
Argus Research Analyst forecast on BAX
Steven Silver
Argus Research
Argus Research
―
Hold
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Baxter International (NYSE: BAX) and Capricor Therapeutics (NASDAQ: CAPR)
Barclays Analyst forecast on BAX
Matt Miksic
Barclays
Barclays
$25→$27
Buy
20.54%
Upside
Reiterated
05/04/26
Analysts Are Bullish on Top Healthcare Stocks: Alkermes (ALKS), Baxter International (BAX)
Jefferies Analyst forecast on BAX
Matthew Taylor
Jefferies
Jefferies
$21→$19
Hold
-15.18%
Downside
Reiterated
02/12/26
Baxter price target lowered to $19 from $21 at JefferiesBaxter price target lowered to $19 from $21 at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Baxter International

3 Months
Matt MiksicBarclays
Success Rate
9/29 ratings generated profit
31%
Average Return
-1.83%
Copying Matt Miksic's trades and holding each position for 3 Months would result in 31.03% of your transactions generating a profit, with an average return of -1.83% per trade.
1 Year
Matt MiksicBarclays
Success Rate
15/29 ratings generated profit
52%
Average Return
+3.11%
Copying Matt Miksic's trades and holding each position for 1 Year would result in 51.72% of your transactions generating a profit, with an average return of +3.11% per trade.
2 Years
Matt MiksicBarclays
Success Rate
12/29 ratings generated profit
41%
Average Return
-3.10%
Copying Matt Miksic's trades and holding each position for 2 Years would result in 41.38% of your transactions generating a profit, with an average return of -3.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BAX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
1
1
1
0
Buy
4
3
2
1
1
Hold
13
10
9
17
12
Sell
1
0
0
1
1
Strong Sell
0
0
0
0
0
total
18
14
12
20
14
In the current month, BAX has received 1 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. BAX average Analyst price target in the past 3 months is 25.90.
Each month's total comprises the sum of three months' worth of ratings.

BAX Financial Forecast

BAX Earnings Forecast

Next quarter’s earnings estimate for BAX is $0.52 with a range of $0.50 to $0.54. The previous quarter’s EPS was $0.56. BAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year BAX has Performed in-line its overall industry.
Next quarter’s earnings estimate for BAX is $0.52 with a range of $0.50 to $0.54. The previous quarter’s EPS was $0.56. BAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year BAX has Performed in-line its overall industry.

BAX Sales Forecast

Next quarter’s sales forecast for BAX is $2.91B with a range of $2.88B to $2.92B. The previous quarter’s sales results were $2.96B. BAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year BAX has Performed in-line its overall industry.
Next quarter’s sales forecast for BAX is $2.91B with a range of $2.88B to $2.92B. The previous quarter’s sales results were $2.96B. BAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year BAX has Performed in-line its overall industry.

BAX Stock Forecast FAQ

What is BAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Baxter International Inc’s 12-month average price target is 25.90.
    What is BAX’s upside potential, based on the analysts’ average price target?
    Baxter International Inc has 15.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BAX a Buy, Sell or Hold?
          Baxter International Inc has a consensus rating of Hold which is based on 1 buy ratings, 10 hold ratings and 0 sell ratings.
            What is Baxter International Inc’s price target?
            The average price target for Baxter International Inc is 25.90. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $29.00 ,the lowest forecast is $21.00. The average price target represents 15.63% Increase from the current price of $22.4.
              What do analysts say about Baxter International Inc?
              Baxter International Inc’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of BAX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.